<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="210"></col>
<col width="121"></col>
<col width="307"></col>
<tbody>
<tr>
<td stylecode="Toprule Lrule Rrule ">Drugs that Affect Renal<br/>Function</td>
<td colspan="2" stylecode="Toprule Lrule Rrule ">A decline in GFR or tubular secretion, as from ACE inhibitors,<br/>angiotensin receptor blockers, nonsteroidal anti-inflammatory<br/>drugs [NSAIDS], COX-2 inhibitors may impair the excretion of<br/>digoxin.</td>
</tr>
<tr>
<td stylecode="Toprule Lrule Rrule ">Antiarrthymics</td>
<td stylecode="Toprule Lrule Rrule ">Dofetilide</td>
<td stylecode="Toprule Lrule Rrule ">Concomitant administration with digoxin was associated with a higher rate of torsades de pointes</td>
</tr>
<tr>
<td stylecode="Toprule Lrule Rrule "></td>
<td stylecode="Toprule Lrule Rrule ">Sotalol</td>
<td stylecode="Toprule Lrule Rrule ">Proarrhythmic events were more common in patients receiving sotalol and digoxin than on either alone; it is not clear whether this represents an interaction or is related to the presence of CHF, a known risk factor for proarrhythmia, in patients receiving digoxin. </td>
</tr>
<tr>
<td stylecode="Toprule Lrule Rrule "></td>
<td stylecode="Toprule Lrule Rrule ">Dronedarone</td>
<td stylecode="Toprule Lrule Rrule ">Sudden death was more common in patients receiving digoxin with dronedarone than on either alone; it is not clear whether this represents an interaction or is related to the presence of advanced heart disease, a known risk factor for sudden death in patients receiving digoxin. </td>
</tr>
<tr>
<td stylecode="Toprule Lrule Rrule ">Parathyroid Hormone Analog</td>
<td stylecode="Toprule Lrule Rrule ">Teriparatide</td>
<td stylecode="Toprule Lrule Rrule ">Sporadic case reports have suggested that hypercalcemia may predispose patients to digitalis toxicity. Teriparatide transiently increases serum calcium. </td>
</tr>
<tr>
<td stylecode="Toprule Lrule Rrule ">Thyroid supplement</td>
<td stylecode="Toprule Lrule Rrule ">Thyroid</td>
<td stylecode="Toprule Lrule Rrule ">Treatment of hypothyroidism in patients taking digoxin may increase the dose requirements of digoxin. </td>
</tr>
<tr>
<td stylecode="Toprule Lrule Rrule ">Sympathomimetics</td>
<td stylecode="Toprule Lrule Rrule ">Epinephrine<br/>Norepinephrine<br/>Dopamine</td>
<td stylecode="Toprule Lrule Rrule ">Can increase the risk of cardiac arrhythmias</td>
</tr>
<tr>
<td stylecode="Toprule Lrule Rrule ">Neuromuscular Blocking Agents</td>
<td stylecode="Toprule Lrule Rrule ">Succinylcholine</td>
<td stylecode="Toprule Lrule Rrule ">May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. </td>
</tr>
<tr>
<td stylecode="Toprule Lrule Rrule ">Supplements</td>
<td stylecode="Toprule Lrule Rrule ">Calcium</td>
<td stylecode="Toprule Lrule Rrule ">If administered rapidly by intravenous route, can produce serious arrhythmias in digitalized patients. </td>
</tr>
<tr>
<td stylecode="Toprule Lrule Rrule ">Beta-adrenergic blockers and calcium channel blockers</td>
<td stylecode="Toprule Lrule Rrule "></td>
<td stylecode="Toprule Lrule Rrule ">Additive effects on AV node conduction can result in bradycardia and advanced or complete heart block. </td>
</tr>
<tr>
<td stylecode="Toprule Lrule Rrule ">Hyperpolarization-activated cyclic nucleotide-gated channel blocker</td>
<td stylecode="Toprule Lrule Rrule ">Ivabradine</td>
<td stylecode="Toprule Lrule Rrule ">Can increase the risk of bradycardia.</td>
</tr>
</tbody>
</table>